Sodium hypochlorite 0.05% solution
Requires a prescription from a doctor or prescriber
Hypochlorite is an ion composed of chlorine and oxygen with the chemical formula ClO−.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Sodium hypochlorite
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Sodium hypochlorite
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Sodium hypochlorite
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 22 · Randomised trials: 21 · 1986–2026
Showing the 50 most relevant studies, sorted by most relevant.
M. Guivarc’h, U. Ordioni, H. Ahmed, et al.
Journal of Endodontics, 2017
N. Verma, P. Sangwan, S. Tewari, et al.
Journal of Endodontics, 2019
Fiorillo L, D'Amico C, Meto A, et al.
2024
- Sodium Hypochlorite
- Root Canal Irrigants
- Burns, Chemical
Zhou W, Feng S, Chu X, et al.
2025
IntroductionThe bond strength (BS) between composite resin and dentin is a crucial factor determining the long-term success of restorations. Sodium hypochlorite (NaOCl), a frequently used root canal irrigating agent, has been demonstrated to notably influence the properties of dentin, thereby affecting the BS. Moreover, the application of collagen crosslinkers has become a potential approach to improve the stability of the resin-dentin bond. Nevertheless, the effect of collagen crosslinkers on the bond strength (BS) between sodium hypochlorite (NaOCl) treated dentin and composite resin remains a topic of contention, and there is a lack of in-depth understanding in the existing literature. The purpose of this systematic review and meta-analysis was to analyze the current literature on the effect of collagen crosslinkers on the BS between sodium hypochlorite treated dentin and composite resin.MethodsDatabases including PubMed, EMBASE, Cochrane library, Scopus, Web of Science and SinoMed were searched. In vitro studies reported the effect of crosslinking agents on NaOCl-treated dentin BS were included. The reference lists of studies included via databases were manually searched for more studies that fulfilled the inclusion criteria. The initial search yielded 1,538 studies, and subsequent screening resulted in the inclusion of 14 studies. Most of studies (78.6%, 11/14) were categorized as having a "low" risk of bias. The studies included in the meta-analysis employed a range of cross-linking agents, including ethylenediaminetetraacetic acid (EDTA), phytic acid (IP6), proanthocyanidin (PA), rosmarinic acid (RA) and sodium ascorbate (SA). Subgroup comparisons were performed according to NaOCl exposure duration. Studies treated with different concentration of NaOCl were analyzed separately.ResultsFor dentin exposed less than 1 min or NaOCl at lower concentration, significant positive effect cannot be observed when using collagen crosslinkers. For dentin exposed more than 1 min in NaOCl at concentrations greater than 2.5%, EDTA, PA and SA were observed to significantly improve the BS. RA is proved effective in improving the BS of dentin exposed to high concentrations NaOCl within a shorter duration. Current evidence is insufficient to conclude that IP6 has a positive effect in NaOCl-treated dentin bonding performance.ConclusionThe effect of collagen crosslinkers on the BS of NaOCl treated dentin was influenced by the concentration of NaOCl and the duration of exposure.
Abstract licence: CC BY
Teja KV, Vasundhara KA, Patini R, et al.
2026
- Sodium Hypochlorite
- Root Canal Irrigants
- Root Canal Therapy
ObjectiveThe aim of the present systematic review and meta-analysis was to evaluate the effect of different concentrations of sodium hypochlorite (NaOCl) on post-operative pain following root canal treatment.Material and methodsThe current study was conducted according to PRISMA guidelines and registered on PROSPERO (CRD42023451576). The research question was formulated according to PICO strategy and aimed at determining if different concentrations of NaOCl would have influenced post-operative pain in adults following endodontic treatments. A comprehensive literature search was performed manually and through multiple electronic databases, using predefined keywords and MeSH terms. Randomized controlled trials (RCTs) comparing different NaOCl concentrations (ResultsSeven RCTs met the inclusion criteria and were included in the systematic review; moreover, four studies underwent quantitative evaluation (meta-analysis). The results showed no statistically significant difference in post-operative pain between low (ConclusionWithin the limitations of the present study, no significant differences in post-endodontic pain were found between high and low NaOCl concentrations. However, concentrations < 5% might be associated with less pain incidence. Further well-designed clinical trials with standardized methodologies are needed to provide more conclusive evidence.
Abstract licence: CC BY
Aucinaite R, Nedzinskiene E, Peciuliene V, et al.
2025
This systematic review aims to compare the efficacy of sodium hypochlorite (NaOCl) and chlorhexidine digluconate (CHX) in decontaminating gutta-percha (GP) cones against endodontic pathogens-Enterococcus faecalis (E. faecalis), Staphylococcus aureus (S. aureus), and Candida albicans (C. albicans)-within 0-10 min. A systematic search was conducted in six databases (PubMed, Web of Science, Cochrane Library, SCIELO, Scopus, and LILACS), supplemented by manual searches performed independently by three reviewers. No publication year restrictions were applied, and only English-language studies were included. This review followed the PRISMA statement (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). The risk of bias was assessed using six parameters with a modified Cochrane risk of bias tool. Out of 309 potentially eligible studies, 216 were screened by title and abstract, 32 were selected for full-text assessments, and 7 were included. All studies had a moderate or high risk of bias. The majority of the included studies showed that higher NaOCl concentrations effectively eliminate E. faecalis and S. aureus within 1-5 min. However, data on CHX's antimicrobial effect on C. albicans were limited. The qualitative analysis suggests that NaOCl remains the most effective agent for GP decontamination, while CHX with additives shows potential against fungal species.
Abstract licence: CC BY
Yuan Qiu, Jiawei Xu, Yuedan Xu, et al.
PeerJ, 2023
Anna Geevarghis M, Shetty C, Dsouza TS, et al.
2026
Feria Q, Soegiharto IRS, Putri NDA, et al.
2026
Chang CH, Devine M, Woo D, et al.
2026
- Skin Diseases
- Sodium Hypochlorite
- Anti-Infective Agents, Local
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Sodium hypochlorite mediate its antimicrobial action by reacting with fatty acids and amino acids.
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
Protein binding
Volume of distribution
Metabolism
Elimination
Clearance
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
How the body processes this drug — absorption, distribution, metabolism, and elimination
ATC D08AX07
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72